Vaccinating against monkeypox in the Democratic Republic of the Congo

Healthcare-associated transmission of monkeypox has been observed on multiple occasions in areas where the disease is endemic. Data collected by the US Centers for Disease Control and Prevention (CDC) from an ongoing CDC-supported program of enhanced surveillance in the Tshuapa Province of the Democ...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2019-02, Vol.162, p.171-177
Main Authors: Petersen, Brett W., Kabamba, Joelle, McCollum, Andrea M., Lushima, Robert Shongo, Wemakoy, Emile Okitolonda, Muyembe Tamfum, Jean-Jacques, Nguete, Beatrice, Hughes, Christine M., Monroe, Benjamin P., Reynolds, Mary G.
Format: Article
Language:English
Subjects:
Animals
Clinical trial
Clinical Trials as Topic
Democratic Republic of the Congo
Democratic Republic of the Congo - epidemiology
Health Personnel
Health Resources
Humans
Immunogenicity, Vaccine
IMVAMUNE
Monkeypox
Monkeypox virus
Mpox (monkeypox) - epidemiology
Mpox (monkeypox) - prevention & control
Occupational Diseases - epidemiology
Occupational Diseases - prevention & control
Occupational Diseases - virology
Risk Factors
Rural Population
Smallpox vaccine
Smallpox Vaccine - administration & dosage
Smallpox Vaccine - immunology
Vaccination
Vaccines, Attenuated - administration & dosage
Vaccines, Attenuated - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Healthcare-associated transmission of monkeypox has been observed on multiple occasions in areas where the disease is endemic. Data collected by the US Centers for Disease Control and Prevention (CDC) from an ongoing CDC-supported program of enhanced surveillance in the Tshuapa Province of the Democratic Republic of the Congo, where the annual incidence of human monkeypox is estimated to be 3.5–5/10,000, suggests that there is approximately one healthcare worker infection for every 100 confirmed monkeypox cases. Herein, we describe a study that commenced in February 2017, the intent of which is to evaluate the effectiveness, immunogenicity, and safety of a third-generation smallpox vaccine, IMVAMUNE®, in healthcare personnel at risk of monkeypox virus (MPXV) infection. We describe procedures for documenting exposures to monkeypox virus infection in study participants, and outline lessons learned that may be of relevance for studies of other investigational medical countermeasures in hard to reach, under-resourced populations. •Healthcare workers in the rural DRC are at risk of occupationally-acquired infection with monkeypox virus.•Potential hazards of first- and second-generation smallpox vaccines preclude their use in this setting.•We have initiated a study of vaccination of HCWs at risk of MPX with IMVAMUNE, a third-generation smallpox vaccine.•This report describes the methods and results of the study to date.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2018.11.004